Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
6 C' B0 @- K: Y/ P$ J% K+ T- uNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 % x- N% Z9 a1 f# q' T0 K
+ Author Affiliations, A4 g0 x+ b0 `# L
( h( s8 R- Q( F3 `' d1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
1 ?, @; z7 w0 l A# m r2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ J) R$ h* H$ o3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 U, D9 U) \5 T# X6 y+ o4 u4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
5 z- ~8 `; H4 R; ~, u5 d0 f( \) g5 ~5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan \7 h/ n5 z( S% I
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
1 l9 H/ {% y, Y- b9 R+ z7Kinki University School of Medicine, Osaka 589-8511, Japan % p, A4 Q: W' C! ]/ A
8Izumi Municipal Hospital, Osaka 594-0071, Japan
9 r) W% |2 i+ |; d" i/ |9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
6 [0 I3 S; y# k7 v+ X6 r: fCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 2 k7 G3 H% h; r
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
+ P6 g, W9 o/ ]+ f; g' l* F* |& N- P
|